ArticleFrontiers in veterinary science2019
Bluetongue Disease Control in Northern Ireland During 2017 and 2018.
Article in Frontiers in veterinary science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 citations in OpenAlex.
- The changing landscape of bluetongue in northern Europe.Journal of medical entomology · 2026Review
- Farmers' views and attitudes towards bovine tuberculosis and bluetongue in Northern Ireland using semi-structured interviews.Irish veterinary journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the emergence of bluetongue virus in central and northern Europe in 2006, Northern Ireland's (NI) surveillance programme has evolved to include the use of risk assessments and simulation models to monitor the risk of bluetongue incursion. Livestock production is of high economic importance to NI as it exports approximately 75% of its agricultural produce. Its surveillance programme is designed to enable effective mitigation measures to be identified to minimize disease risk, and to provide additional assurances to protect NI's export markets in the European Union (EU) and third countries. Active surveillance employs an atmospheric dispersion model to assess the likelihood of wind-borne midge transfer from Great Britain (GB) to NI and to identify high risk areas. In these areas, the number of cattle tested for bluetongue is proportionally increased. Targeted surveillance is directed to ruminants imported from restricted countries and regions at risk of bluetongue. Targeted surveillance on high risk imports assists in early detection of disease as, despite all controls and preventive measures, legally imported animals may still carry the virus. In November 2018, a bluetongue-positive heifer was imported into NI. A case specific risk assessment was commissioned to estimate the likelihood of spread of bluetongue as a result of this incursion. November is the tail end of the midges' active period and therefore there was considerable uncertainty pertaining to the survival of midges inside a cattle shed and the potential for incubation of the virus in the vectors. An evidenced-based approach was adopted where temperature and midge abundance was monitored in order to minimize uncertainty and give an accurate estimate of the likelihood of virus spread to other animals following the arrival of the positive heifer. The heifer was destroyed and the evidence indicated that the risk of successful completion of the extrinsic cycle within the local midge population was negligible. This paper describes NI's surveillance programme between January 2017 and December 2018 and the case of a positive imported animal into the country. The importance of effective surveillance in early detection of threats and the usefulness of risk assessments is highlighted through the case study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.